Using engineered stem cells to treat advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of interferon alpha expressing mesenchymal stromal cells (MSC-IFNα) in patients with locally advanced or metastatic solid tumors. The study will assess the feasibility of MSC-IFNα treatment, its anti-tumor effects when combined with immunochemotherapy, and the pharmacokinetics and pharmacodynamics of the treatment. The trial is designed as a first-in-human, single-center, prospective, open-label study, focusing on patients who have not responded to standard therapies. By utilizing genetically modified MSCs, the study seeks to enhance the delivery of interferon to the tumor microenvironment, potentially improving treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age from 18 to 75 years with estimated life expectancy \>3 months.
2. Histopathological confirmed locally advanced or metastatic solid tumors including, but not limited to, lung cancer, breast cancer, colorectal cancer, hepatocellular carcinoma, and sarcomas.
3. Failed to at least first-line and second-line treatments or initially diagnosed locally advanced/metastatic solid tumors that have no National Comprehensive Cancer Network(NCCN) guideline-recommended therapy.
4. Have at least one measurable target lesion.
5. Previous treatment must be completed for more than 4 weeks prior to the enrollment of this study.
6. Have an Eastern Cooperative Oncology Group performance status (ECOG) of 0 to 2 at the time of enrollment.
7. Have adequate organ function, which should be confirmed within 2 weeks prior to the first dose of study drugs.
8. Previous treatment with anti-PD-1/PD-L1 antibodies is allowed.
9. Ability to understand and sign a written informed consent document.
10. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and up to 90 days after the last dose of the drug.

Exclusion Criteria:

1. Active, known, or suspected autoimmune diseases.
2. Known brain metastases or active central nervous system (CNS). Subjects with CNS metastases who were treated with radiotherapy for at least 3 months prior to enrollment, have no central nervous symptoms, and are off corticosteroids, are eligible for enrollment, but require a brain MRI screening.
3. Subjects are being treated with either corticosteroid (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.
4. History of psychiatric disorders including depression, suicidality, and mania.
5. History of allergy or intolerance to study drug components.
6. Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
7. Uncontrolled concurrent illness, including ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding insignificant sinus bradycardia and sinus tachycardia), or psychiatric illness/social situations and any other illness that would limit compliance with study requirements and jeopardize the safety of the patient.
8. History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
9. Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy test performed within 7 days before enrollment, and a negative result must be documented.
10. Previous or concurrent cancer within 3 years prior to treatment start.

Where it's running

• Department of Biotherapeutic, Chinese PLA General Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: WeiDong Han, PhD — Chinsese PLA Gereral Hospital
• Study coordinator: WeiDong Han, PhD
• Email: hanwdrsw@sina.com
• Phone: 010-66937231

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ASP388B given alone or with standard therapies in solid tumors

  This early study tests ASP388B, first given alone or with standard cancer treatments, to see if it is safe and to find workable dose levels for solid tumors.

  Recruiting at 4 sites Phase 1/2 Astellas Pharma Inc · Lake Success, New York and 3 other locations · NCT07730021

• First-in-human test of EMB-15 in adults with advanced or metastatic solid tumors

  This early phase trial tests EMB-15 to see if it is safe and tolerable in adults whose solid tumors have progressed after standard care or have no standard therapy.

  Recruiting Phase 1 Shanghai EpimAb Biotherapeutics Co., Ltd. · Guangzhou, Guangdong · NCT07607054

• BC3195 plus pembrolizumab in advanced solid tumors

  This trial tests whether adding BC3195 to pembrolizumab is safe and shows preliminary activity in adults with locally advanced or metastatic solid tumors.

  Recruiting Phase 1/2 Biocity Biopharmaceutics Co., Ltd. · Guangzhou, Guangdong · NCT07469774

• YL202 for advanced non‑small cell lung, colorectal, cervical, and other solid tumors

  This trial will try YL202, an antibody‑drug conjugate that targets HER3, in adults with advanced non‑small cell lung, colorectal, cervical, or other metastatic solid tumors who have received one or two prior systemic treatments.

  Recruiting Phase 2 MediLink Therapeutics (Suzhou) Co., Ltd. · Changsha, Hunan · NCT07202364

• MRG007 (ARR-217) treatment for advanced solid tumors

  This trial will test MRG007 (ARR-217), an antibody-drug conjugate that targets CDH17, in adults with unresectable locally advanced or metastatic solid tumors who have exhausted standard therapies.

  Recruiting at 21 sites Phase 1 ArriVent BioPharma, Inc. · Los Angeles, California and 20 other locations · NCT07066657

• Evaluating XB010 for patients with solid tumors

  This study is testing a new drug called XB010, alone and with another medication, to see if it can help people with advanced solid tumors who have few other treatment options.

  Recruiting at 18 sites Phase 1 Exelixis · Irvine, California and 19 other locations · NCT06545331

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.